
Exelixis Inc
EXELHealthcare|Biotechnology|USA
$56.51
-0.60 (-1.05%)
DCF (FCF)
$29.26
Tangible Book
$7.38
Graham Number
$23.55
Earnings Power
$17.69
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
2597.48,
2918.06,
3233.42,
3423.31,
3031.78
],
"ebit_estimate": [
1041.09,
1170.91,
1391.19,
1582.6,
1515.67
],
"ebitda_estimate": [
1103.59,
1209.28,
1520.63,
null,
null
],
"net_income_estimate": [
853.37,
961.56,
1171.22,
1401.19,
1377.05
],
"per_share_eps_estimate": [
3.24,
3.65,
4.45,
5.37,
5.09
],
"eps_nri_estimate": [
3.19,
3.73,
4.59,
5.44,
5.02
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
11.2,
15.03,
20.02,
null,
null
],
"pretax_income_estimate": [
1086.79,
1212.29,
1443.27,
1664.15,
1901.54
],
"operating_cash_flow_per_share_estimate": [
3.26,
3.85,
5.21,
7.66,
10.61
],
"roa_estimate": [
25.4,
24.8,
23.5,
25.8,
26.6
],
"roe_estimate": [
30.64,
27.78,
26.65,
25.9,
26.7
],
"gross_margin_estimate": [
96,
95.67,
95.69,
95.9,
95.88
],
"operating_cash_flow_estimate": [
872.35,
1028.31,
1392.75,
2047.69,
2836.29
],
"pettm_estimate": [
17.46,
15.49,
12.69,
10.52,
11.11
],
"long_term_growth_rate_mean": 18.04,
"long_term_revenue_growth_rate_mean": "11.76",
"future_per_share_eps_estimate_growth": 16.55,
"future_eps_nri_estimate_growth": 18.04,
"future_revenue_estimate_growth": 11.76,
"future_ebit_estimate_growth": 16.4,
"future_ebitda_estimate_growth": 18.07,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 14.21,
"future_pretax_income_estimate_growth": 14.93,
"future_book_value_per_share_estimate_growth": 34.44,
"future_roa_estimate_growth": -4.33,
"future_roe_estimate_growth": -9.16,
"future_gross_margin_estimate_growth": -0.25,
"future_operating_cash_flow_per_share_estimate_growth": 18.34
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
633.17,
661.27,
689.23,
697.12,
722.27,
745.3,
777.92,
802.49
],
"ebit_estimate": [
254.07,
257.03,
250.53,
273.56,
297.5,
310.55,
274.23,
null
],
"ebitda_estimate": [
262.18,
272.81,
292.69,
266.36,
null,
null,
null,
null
],
"net_income_estimate": [
202.82,
205.15,
200.38,
226.62,
240.82,
251.62,
223.57,
null
],
"per_share_eps_estimate": [
0.77,
0.8,
0.81,
0.9,
0.98,
1.06,
0.69,
null
],
"eps_nri_estimate": [
0.79,
0.81,
0.81,
0.9,
0.95,
0.99,
0.74,
null
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
264.63,
268.24,
265.31,
288.69,
306.89,
320.69,
285.27,
null
],
"operating_cash_flow_per_share_estimate": [
0.72,
0.82,
0.7,
0.98,
0.99,
0.99,
0.73,
null
],
"roa_estimate": [
7.3,
6.9,
6,
null,
null,
null,
null,
null
],
"roe_estimate": [
9.3,
8.5,
7.3,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
95.83,
95.77,
96.17,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
192.47,
217.87,
187.13,
261.98,
264.65,
264.65,
195.15,
null
],
"pettm_estimate": [
17.29,
16.21,
15.06,
15.54,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 18.04,
"long_term_revenue_growth_rate_mean": "11.76",
"future_per_share_eps_estimate_growth": 16.55,
"future_eps_nri_estimate_growth": 18.04,
"future_revenue_estimate_growth": 11.76,
"future_ebit_estimate_growth": 16.4,
"future_ebitda_estimate_growth": 18.07,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 14.21,
"future_pretax_income_estimate_growth": 14.93,
"future_book_value_per_share_estimate_growth": 34.44,
"future_roa_estimate_growth": -4.33,
"future_roe_estimate_growth": -9.16,
"future_gross_margin_estimate_growth": -0.25,
"future_operating_cash_flow_per_share_estimate_growth": 18.34
}